Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...

Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta ...

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug ...

"We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized ...

Becomes the first subcutaneously administered PD-1 inhibitor.

Halozyme (HALO) announced that Argenx’s (ARGX) Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Health ...